{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:00:44Z","timestamp":1791054044387,"version":"4.1.0"},"reference-count":72,"publisher":"Japan Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej19-0234","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T22:03:02Z","timestamp":1566252182000},"page":"843-852","source":"Crossref","is-referenced-by-count":19,"title":["Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases"],"prefix":"10.1507","volume":"66","author":[{"given":"Hidefumi","family":"Inaba","sequence":"first","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takeshima","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwakura","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, 641-8509, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Akamizu T, Mori T, Nakao K (1997) Pathogenesis of Graves\u2019 disease: molecular analysis of anti-thyrotropin receptor antibodies. Endocr J 44: 633\u2013646.","DOI":"10.1507\/endocrj.44.633"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Inaba H, De Groot LJ, Akamizu T (2016) Thyrotropin receptor epitope and human leukocyte antigen in Graves\u2019 disease. Front Endocrinol (Lausanne) 7: 120.","DOI":"10.3389\/fendo.2016.00120"},{"key":"3","unstructured":"3 Akamizu T, Amino N (2017) Hashimoto\u2019s thyroiditis. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, <i>et al.<\/i> (eds) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2000\u20132017 Jul 17."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 McLachlan SM, Rapoport B (2014) Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 35: 59\u2013105.","DOI":"10.1210\/er.2013-1055"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Inaba H, Martin W, De Groot AS, Qin S, De Groot LJ (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves\u2019 disease. J Clin Endocrinol Metab 91: 2286\u20132294.","DOI":"10.1210\/jc.2005-2537"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y (2015) Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun 64: 82\u201390.","DOI":"10.1016\/j.jaut.2015.07.009"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7 Akamizu T, Sale MM, Rich SS, Hiratani H, Noh JY, et al. (2000) Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid 10: 851\u2013858.","DOI":"10.1089\/thy.2000.10.851"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Maciel LM, Rodrigues SS, Dibbern RS, Navarro PA, Donadi EA (2001) Association of the HLA-DRB1*0301 and HLA-DQA1*0501 alleles with Graves\u2019 disease in a population representing the gene contribution from several ethnic backgrounds. Thyroid 11: 31\u201335.","DOI":"10.1089\/10507250150500630"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Zeitlin AA, Heward JM, Newby PR, Carr-Smith JD, Franklyn JA, et al. (2008) Analysis of HLA class II genes in Hashimoto\u2019s thyroiditis reveals differences compared to Graves\u2019 disease. Genes Immun 9: 358\u2013363.","DOI":"10.1038\/gene.2008.26"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Blank CU, Enk A (2015) Therapeutic use of anti-CTLA-4 antibodies. Int Immunol 27: 3\u201310.","DOI":"10.1093\/intimm\/dxu076"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813\u2013824.","DOI":"10.1093\/intimm\/dxm057"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Akamizu T, Ikuyama S, Saji M, Kosugi S, Kozak C, et al. (1990) Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. Proc Natl Acad Sci U S A 87: 5677\u20135681.","DOI":"10.1073\/pnas.87.15.5677"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nagayama Y, Kaufman KD, Seto P, Rapoport B (1989) Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun 165: 1184\u20131190.","DOI":"10.1016\/0006-291X(89)92727-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Davies TF, Latif R (2019) TSH receptor and autoimmunity. Front Endocrinol (Lausanne) 10: 19.","DOI":"10.3389\/fendo.2019.00019"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Rapoport B, McLachlan SM (2016) TSH receptor cleavage into subunits and shedding of the A-subunit; a molecular and clinical perspective. Endocr Rev 37: 114\u2013134.","DOI":"10.1210\/er.2015-1098"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Inaba H, Martin W, Ardito M, De Groot AS, De Groot LJ (2010) The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves\u2019 disease. J Clin Endocrinol Metab 95: 2909\u20132916.","DOI":"10.1210\/jc.2009-2393"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Inaba H, Pan D, Shin YH, Martin W, Buchman G, et al. (2009) Immune response of mice transgenic for human histocompatibility leukocyte Antigen-DR to human thyrotropin receptor-extracellular domain. Thyroid 19: 1271\u20131280.","DOI":"10.1089\/thy.2008.0349"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Inaba H, Moise L, Martin W, De Groot AS, Desrosiers J, et al. (2013) Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides. Endocrinology 154: 2234\u20132243.","DOI":"10.1210\/en.2013-1033"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Pichurin P, Pham N, David CS, Rapoport B, McLachlan SM (2006) HLA-DR3 transgenic mice immunized with adenovirus encoding the thyrotropin receptor: T cell epitopes and functional analysis of the CD40 Graves\u2019 polymorphism. Thyroid 16: 1221\u20131227.","DOI":"10.1089\/thy.2006.16.1221"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20 Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, et al. (2004) Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto\u2019s thyroiditis (Th1) and Graves\u2019 disease (Th2). Neuroimmunomodulation 11: 209\u2013213.","DOI":"10.1159\/000078438"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN (2013) Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid 23: 871\u2013878.","DOI":"10.1089\/thy.2012.0514"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Ueda Y, Uraki S, Inaba H, Nakashima S, Ariyasu H, et al. (2017) Graves\u2019 disease in pediatric and elderly patients with 22q11.2 deletion syndrome. Intern Med 56: 1169\u20131173.","DOI":"10.2169\/internalmedicine.56.7927"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Akamizu T (2001) Antithyrotropin receptor antibody: an update. Thyroid 11: 1123\u20131134.","DOI":"10.1089\/10507250152740966"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, et al. (2011) A new small-molecule antagonist inhibits Graves\u2019 disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96: 548\u2013554.","DOI":"10.1210\/jc.2010-1935"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25 Holthoff HP, Li Z, Fa\u00dfbender J, Reimann A, Adler K, et al. (2017) Cyclic peptides for effective treatment in a long-term model of graves disease and orbitopathy in female mice. Endocrinology 158: 2376\u20132390.","DOI":"10.1210\/en.2016-1845"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Jansson L, Vrolix K, Jahraus A, Martin KF, Wraith DC (2018) Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice. Endocrinology 159: 3446\u20133457.","DOI":"10.1210\/en.2018-00306"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Gonzalez-Rodriguez E, Rodriguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804\u2013816.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"28","unstructured":"28 Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, et al. (2018) Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo 32: 345\u2013351."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, et al. (2018) Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern Med 57: 2029\u20132034.","DOI":"10.2169\/internalmedicine.9518-17"},{"key":"30","unstructured":"30 Inaba H, Ariyasu H, Kurimoto C, Iwakura H, Akamizu T (2018) Endocrine organ dysfunction with immune-checkpoint inhibitors. Gan To Kagaku Ryoho 45: 1031\u20131035 (In Japanese)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Inaba H, Ariyasu H, Okuhira H, Yamamoto Y, Akamatsu H, et al. (2018) Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother 2: 565.","DOI":"10.24294\/ti.v2.i2.606"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Arima H, Iwama S, Inaba H, Ariyasu H, Makita N, et al. (2019) Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J In press.","DOI":"10.1507\/endocrj.EJ19-0163"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, et al. (2018) Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2: 241\u2013251.","DOI":"10.1210\/js.2017-00432"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, et al. (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 14: e0216954.","DOI":"10.1371\/journal.pone.0216954"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Kari S, Flynn JC, Zulfiqar M, Snower DP, Elliott BE, et al. (2013) Enhanced autoimmunity associated with induction of tumor immunity in thyroiditis-susceptible mice. Thyroid 23: 1590\u20131599.","DOI":"10.1089\/thy.2013.0064"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36 Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, et al. (2017) Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27: 894\u2013901.","DOI":"10.1089\/thy.2016.0562"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Bicek A, Zaletel K, Gaberscek S, Pirnat E, Krhin B, et al. (2009) 49A\/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Hum Immunol 70: 820\u2013824.","DOI":"10.1016\/j.humimm.2009.06.016"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Hayashi M, Kouki T, Takasu N, Sunagawa S, Komiya I (2008) Association of an A\/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves\u2019 disease in Japanese patients. Eur J Endocrinol 158: 817\u2013822.","DOI":"10.1530\/EJE-07-0649"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39 Vita R, Guarneri F, Agah R, Benvenga S (2014) Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid 24: 390\u2013394.","DOI":"10.1089\/thy.2013.0170"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, et al. (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344: 732\u2013738.","DOI":"10.1056\/NEJM200103083441005"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Brito-Zer\u00f3n P, Ramos-Casals M, Bosch X, Stone JH (2014) The clinical spectrum of IgG4-related disease. Autoimmun Rev 13: 1203\u20131210.","DOI":"10.1016\/j.autrev.2014.08.013"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366: 539\u2013551.","DOI":"10.1056\/NEJMra1104650"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Mattoo H, Stone JH, Pillai S (2017) Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease. Autoimmunity 50: 19\u201324.","DOI":"10.1080\/08916934.2017.1280029"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, et al. (2018) Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med 10: eaaq0997.","DOI":"10.1126\/scitranslmed.aaq0997"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, et al. (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22: 21\u201330.","DOI":"10.3109\/s10165-011-0571-z"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Komatsu K, Hamano H, Ochi Y, Takayama M, Muraki T, et al. (2005) High prevalence of hypothyroidism in patients with autoimmune pancreatitis. Dig Dis Sci 50: 1052\u20131057.","DOI":"10.1007\/s10620-005-2703-9"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Watanabe T, Maruyama M, Ito T, Fujinaga Y, Ozaki Y, et al. (2013) Clinical features of a new disease concept, IgG4-related thyroiditis. Scand J Rheumatol 42: 325\u2013330.","DOI":"10.3109\/03009742.2012.761281"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Li Y, Nishihara E, Hirokawa M, Taniguchi E, Miyauchi A, et al. (2010) Distinct clinical, serological, and sonographic characteristics of Hashimoto\u2019s thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab 95: 1309\u20131317.","DOI":"10.1210\/jc.2009-1794"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Deshpande V, Huck A, Ooi E, Stone JH, Faquin WC, et al. (2012) Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease. J Clin Pathol 65: 725\u2013728.","DOI":"10.1136\/jclinpath-2011-200485"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Takeshima K, Ariyasu H, Inaba H, Inagaki Y, Yamaoka H, et al. (2015) Distribution of serum immunoglobulin G4 levels in Hashimoto\u2019s thyroiditis and clinical features of Hashimoto\u2019s thyroiditis with elevated serum immunoglobulin G4 levels. Endocr J 62: 711\u2013717.","DOI":"10.1507\/endocrj.EJ15-0157"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51 Kawashima ST, Tagami T, Nakao K, Nanba K, Tamanaha T, et al. (2014) Serum levels of IgG and IgG4 in Hashimoto thyroiditis. Endocrine 45: 236\u2013243.","DOI":"10.1007\/s12020-013-9988-9"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52 Zhang J, Zhao L, Gao Y, Liu M, Li T, et al. (2014) A classification of Hashimoto\u2019s thyroiditis based on immunohistochemistry for IgG4 and IgG. Thyroid 24: 364\u2013370.","DOI":"10.1089\/thy.2013.0211"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Minamino H, Inaba H, Ariyasu H, Furuta H, Nishi M, et al. (2016) A novel immunopathological association of IgG4-RD and vasculitis with Hashimoto\u2019s thyroiditis. Endocrinol Diabetes Metab Case Rep 2016: 160004.","DOI":"10.1530\/EDM-16-0004"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54 Nanba T, Watanabe M, Inoue N, Iwatani Y (2009) Increases of the Th1\/Th2 cell ratio in severe Hashimoto\u2019s disease and in the proportion of Th17 cells in intractable Graves\u2019 disease. Thyroid 19: 495\u2013501.","DOI":"10.1089\/thy.2008.0423"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Okazaki K, Yanagawa M, Mitsuyama T, Uchida K (2014) Recent advances in the concept and pathogenesis of IgG4-related disease in the hepato-bilio-pancreatic system. Gut Liver 8: 462\u2013470.","DOI":"10.5009\/gnl14107"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Inaba H, Hayakawa T, Miyamoto W, Takeshima K, Yamaoka H, et al. (2013) IgG4-related ocular adnexal disease mimicking thyroid-associated orbitopathy. Intern Med 52: 2545\u20132551.","DOI":"10.2169\/internalmedicine.52.0902"},{"key":"57","unstructured":"57 Riedel BM (1896) Chronic and prominent thyroidal inflammation forming iron-hard tumor. The Journal of German Society of Surgery 25: 101\u2013105 (In German)."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Hay ID (1985) Thyroiditis: a clinical update. Mayo Clin Proc 60: 836\u2013843.","DOI":"10.1016\/S0025-6196(12)64789-2"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Hennessey JV (2011) Clinical review: Riedel\u2019s thyroiditis. J Clin Endocrinol Metab 96: 3031\u20133041.","DOI":"10.1210\/jc.2011-0617"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH (2010) Riedel\u2019s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 62: 1312\u20131318.","DOI":"10.1002\/acr.20215"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Takeshima K, Inaba H, Ariyasu H, Furukawa Y, Doi A, et al. (2015) Clinicopathological features of Riedel\u2019s thyroiditis associated with IgG4-related disease in Japan. Endocr J 62: 725\u2013731.","DOI":"10.1507\/endocrj.EJ15-0175"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V (2011) Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976\u20132008. Thyroid 21: 765\u2013772.","DOI":"10.1089\/thy.2010.0453"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63 Pusztaszeri M, Triponez F, Pache JC, Bongiovanni M (2012) Riedel\u2019s thyroiditis with increased IgG4 plasma cells: evidence for an underlying IgG4-related sclerosing disease? Thyroid 22: 964\u2013968.","DOI":"10.1089\/thy.2011.0404"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Stan MN, Sonawane V, Sebo TJ, Thapa P, Bahn RS (2017) Riedel\u2019s thyroiditis association with IgG4-related disease. Clin Endocrinol (Oxf) 86: 425\u2013430.","DOI":"10.1111\/cen.13238"},{"key":"65","doi-asserted-by":"publisher","unstructured":"65 Takeshima K, Inaba H, Furukawa Y, Nishi M, Yamaoka H, et al. (2014) Elevated serum immunoglobulin G4 levels in patients with Graves\u2019 disease and their clinical implications. Thyroid 24: 736\u2013743.","DOI":"10.1089\/thy.2013.0448"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Torimoto K, Okada Y, Kurozumi A, Narisawa M, Arao T, et al. (2017) Clinical features of patients with Basedow\u2019s disease and high serum IgG4 levels. Intern Med 56: 1009\u20131013.","DOI":"10.2169\/internalmedicine.56.7824"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Hiratsuka I, Yamada H, Itoh M, Shibata M, Takayanagi T, et al. (2018) Changes in serum immunoglobulin G4 levels in patients with newly diagnosed Graves\u2019 disease. Exp Clin Endocrinol Diabetes 2018 Sep 20. [Epub ahead of print].","DOI":"10.1055\/a-0669-9333"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Nishihara E, Hirokawa M, Takamura Y, Ito M, Nakamura H, et al. (2013) Immunoglobulin G4 thyroiditis in a Graves\u2019 disease patient with large goiter developing hypothyroidism. Thyroid 23: 1496\u20131497.","DOI":"10.1089\/thy.2013.0181"},{"key":"69","doi-asserted-by":"publisher","unstructured":"69 Yu SH, Kang JG, Kim CS, Ihm SH, Choi MG, et al. (2017) Clinical Implications of Immunoglobulin G4 to Graves\u2019 Ophthalmopathy. Thyroid 27: 1185\u20131193.","DOI":"10.1089\/thy.2017.0126"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Bozkirli E, Bakiner OS, Ersozlu Bozkirli ED, Eksi Haydardedeoglu F, Sizmaz S, et al. (2015) Serum immunoglobulin G4 levels are elevated in patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 83: 962\u2013967.","DOI":"10.1111\/cen.12671"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Latrofa F, Chazenbalk GD, Pichurin P, Chen CR, McLachlan SM, et al. (2004) Affinity-enrichment of thyrotropin receptor autoantibodies from Graves\u2019 patients and normal individuals provides insight into their properties and possible origin from natural antibodies. J Clin Endocrinol Metab 89: 4734\u20134745.","DOI":"10.1210\/jc.2003-032068"},{"key":"72","doi-asserted-by":"publisher","unstructured":"72 McLachlan SM, Bahn R, Rapoport B (1992) Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity 14: 143\u2013148.","DOI":"10.3109\/08916939209083133"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/10\/66_EJ19-0234\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:42:59Z","timestamp":1572666179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/10\/66_EJ19-0234\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0234","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}